Clinical trials: Endometriosis Associated Pelvic Pain
Endometriosis
SPIRIT EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Endometriosis-Associated Pain
The purpose of this study is to evaluate the long-term efficacy and safety of relugolix 40 milligram (mg) once daily co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) for up to 104 weeks on…
- Trial name
- NCT03654274
- Testing
- Relugolix, Estradiol/norethindrone acetate
- Where
- 169 sites in United States, Argentina and 18 more
- Volunteers
- 802 people
- Sponsor
- Myovant Sciences GmbH
Pelvic Pain Associated With Endometriosis or Adenomyosis, Pelvic Pain Associated With Refractory Endometriosis
Efficacy and Tolerability of TENS in Endometriosis-related Pain
ELECTRE is a single-center, randomized, prospective, longitudinal, controlled, two-arm, single-blind study lasting 4 weeks (P1 investigation phase) after a 4-week run-in period.
- Conditions
- Pelvic Pain Associated With Endometriosis or Adenomyosis, Pelvic Pain Associated With Refractory Endometriosis, Endometriosis
- Trial name
- ELECTRE (NCT07393295)
- Testing
- Conventional TENS, Microstimulation TENS
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Monath Electronic
Endometriosis
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
A randomized study evaluating the safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in adult premenopausal female participants.
- Trial name
- ELARIS EM-I (NCT01620528)
- Testing
- elagolix
- Volunteers
- 872 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Endometriosis
Study to Investigate the Efficacy of a Non-hormonal Drug Against Endometriosis Associated Pelvic Pain
This study was designed as a proof-of-concept trial to evaluate safety, tolerability, and the efficacy of 1800 mg (ZK 811752 600 mg given orally three times daily) over 12 weeks for the treatment of endometriosis associated…
- Trial name
- NCT00185341
- Testing
- CCR1-Antagonist (BAY86-5047, ZK811752)
- Where
- 32 sites in Czechia, Denmark and 5 more
- Volunteers
- 110 people
- Sponsor
- Bayer
Endometriosis
Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)
The primary objective of this extension study is to assess the maintenance of efficacy of linzagolix administered orally once daily for up to an additional 6 months (for up to 12 months of treatment in total) in women who have…
- Trial name
- NCT04335591
- Testing
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg)
- Where
- 47 sites in United States, Austria and 7 more
- Volunteers
- 356 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Endometriosis
A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis
The primary objective of this study is to assess the efficacy and safety of a range of oral doses of OBE2109 versus placebo, in reducing endometriosis associated pain.
- Trial name
- EDELWEISS (NCT02778399)
- Testing
- OBE2109
- Where
- 86 sites in United States, Poland and 2 more
- Volunteers
- 328 people
- Sponsor
- ObsEva SA
Dysmenorrhea
Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Dysmenorrhea
The purpose of this study is to determine whether combination oral contraceptive pill of Norethindrone \& Ethinyl estradiol is effective in the treatment of dysmenorrhea associated with endometriosis.
- Trial name
- NCT00212342
- Testing
- Norethisterone,Ethinylestradiol, Sugar pill
- Volunteers
- 100 people
- Sponsor
- Nobelpharma
Endometriosis
Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.
The primary objective of this study is to demonstrate the efficacy and safety of linzagolix administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in combination with add-back hormone replacement…
- Trial name
- NCT03992846
- Testing
- 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg)
- Where
- 71 sites in United States, Austria and 8 more
- Volunteers
- 486 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Endometriosis Related Pain
SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain
The purpose of this study is to determine the benefit and safety of relugolix 40 milligrams (mg) once daily, co-administered with low-dose estradiol (E2) and norethindrone acetate (NETA) compared with placebo for 24 weeks, on…
- Trial name
- NCT03204318
- Testing
- Relugolix, Estradiol/norethindrone acetate
- Where
- 123 sites in United States, Argentina and 11 more
- Volunteers
- 638 people
- Sponsor
- Myovant Sciences GmbH
Endometriosis
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain
The objective of this study is to evaluate safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in adult premenopausal female participants including the safety and efficacy of…
- Trial name
- NCT03213457
- Testing
- Estradiol/Norethindrone Acetate, Elagolix
- Where
- 197 sites in United States, Canada and 1 more
- Volunteers
- 681 people
- Sponsor
- AbbVie
Endometriosis Associated Pelvic Pain
A Study to Learn More About How Safe Dienogest is and How Well it Works Under Real World Conditions in Indian Women With Endometriosis
Endometriosis is a condition that affects women, usually during their reproductive years. In women with endometriosis, the tissue that normally covers the inside of the womb grows outside the womb.
- Trial name
- VISAGE (NCT04808843)
- Testing
- Dienogest (BAY86-5258, Visanne)
- Where
- India
- Volunteers
- 160 people
- Sponsor
- Bayer
Endometriosis
Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain
A randomized study evaluating the continued safety and efficacy of elagolix in the management of moderate to severe endometriosis associated pain in adult pre-menopausal women who completed 6 months treatment in pivotal Study…
- Trial name
- NCT02143713
- Testing
- Elagolix
- Volunteers
- 496 people
- Sponsor
- AbbVie
Dysmenorrhea
Multi-center Clinical Trials of Sanjie Analgesic Capsule in Treating Endometriosis
It is a multi-center, double -blind, placebo -controlled, randomized post-marketing study in Chinese subjects with endometriosis-associated pain to assess treatment effect and safety in the subjects treated with Sanjie Analgesic…
- Trial name
- NCT02031523
- Testing
- Sanjie analgesic capsule
- Where
- 14 sites in China
- Volunteers
- 400 people
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
Dysmenorrhea, Dyspareunia
Study Evaluating the Safety and Efficacy of ERB-041 on Reduction of Symptoms Associated With Endometriosis in Reproductive-Aged Women
The purpose of the study is to evaluate the efficacy and safety of two doses of ERB-041 (75 mg and 150 mg) relative to placebo on the relief of endometriosis-related symptoms (dysmenorrhea, pelvic pain, and deep dyspareunia) in…
- Conditions
- Dysmenorrhea, Dyspareunia, Endometriosis, Pelvic Pain
- Trial name
- NCT00318500
- Testing
- ERB-041
- Where
- 70 sites in United States, Australia and 5 more
- Volunteers
- 150 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pelvic Pain Associated With Refractory Endometriosis
A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis
The purpose of this study is to determine efficacy, safety, tolerability and pharmacokinetics of multiple doses of BGS649 with concurrent daily administration of combined oral contraception in patients with refractory…
- Trial name
- NCT01116440
- Testing
- BGS649
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 27 people
- Sponsor
- Mereo BioPharma
Dysmenorrhea
Efficacy and Safety,Long-term Study of Low-dose Oral Contraceptive Pill to Treat Dysmenorrhea.
The purpose of this long-term study is to determine whether combination oral contraceptive pill of Norethindrone \& Ethinyl estradiol is effective in the treatmentof dysmenorrhea associated with endometriosis.
- Trial name
- NCT00212277
- Testing
- Norethindrone,Ethinyl Estradiol
- Sponsor
- Nobelpharma
Endometriosis
A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain
This is a Phase 3, dose-escalation study designed to evaluate the safety and efficacy of both elagolix alone and elagolix plus estradiol/norethindrone acetate (E2/NETA) over 24 months in the management of endometriosis with…
- Trial name
- NCT03343067
- Testing
- elagolix, estradiol/norethindrone acetate (E2/NETA)
- Where
- 37 sites in United States
- Volunteers
- 11 people
- Sponsor
- AbbVie
Endometriosis
Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain
A randomized study evaluating the continued safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in pre-menopausal women.
- Trial name
- NCT01760954
- Testing
- Elagolix
- Volunteers
- 506 people
- Sponsor
- AbbVie
Endometriosis Pelvic, Endometriosis Ovaries
PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates
PRECISION-E2 is a Phase IIa randomized, placebo-controlled study evaluating the pharmacodynamic profile, safety and tolerability of teverelix in premenopausal women with moderate-to-severe pain associated with endometriosis in…
- Conditions
- Endometriosis Pelvic, Endometriosis Ovaries, Premenopausal, Endometriosis (Diagnosis)
- Trial name
- NCT07914062
- Testing
- Teverelix DP
- Volunteers
- 84 people
- Sponsor
- Antev Ltd.
Endometriosis
A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain
The main objective for this study is to assess the efficacy and dose-response relationship of ASP1707 in reduction of endometriosis associated pelvic pain.
- Trial name
- NCT01767090
- Testing
- ASP1707, Leuprorelin acetate
- Where
- 85 sites in Belgium, Bulgaria and 7 more
- Volunteers
- 912 people
- Sponsor
- Astellas Pharma Europe B.V.